Publications by authors named "Ulrike Pailer"
Background Fibroblast growth factor 23 (FGF-23) is crucial in regulating phosphate and vitamin D metabolism and is moreover associated with an increased cardiovascular risk. The specific objective of this study was to investigate the influence of FGF-23 on cardiovascular outcomes, including hospitalization for heart failure (HHF), postoperative atrial fibrillation, and cardiovascular death, in an unselected patient population after cardiac surgery. Methods and Results Patients undergoing elective coronary artery bypass graft and/or cardiac valve surgery were prospectively enrolled.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates how heart failure (HF) and diabetes relate to cardiovascular (CV) death and hospitalization for heart failure (HHF) in patients with atrial fibrillation (AF) over a 4.5-year period.
- - Researchers analyzed data from 7,412 patients and found that both diabetes and HF significantly increase the risk of CV death and HHF, with HF patients facing a higher risk of HHF.
- - The N-terminal pro-B-type natriuretic peptide (NT-proBNP) was effective in assessing risk, improving predictive performance when added to traditional risk factors, indicating its clinical value in this patient population.
Purpose: The benefit of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with heart failure (HF) with reduced ejection fraction (HFrEF) and type 2 diabetes mellitus (T2DM) has been unequivocally proven in randomized, controlled trials. However, real-world evidence assessing the implementation of SGLT2i in clinical practice and their benefit in HF outside of highly selected study populations is limited.
Methods: Patients with HF and T2DM admitted to the cardiology ward of the Medical University of Vienna between 01/2014 and 04/2020 were included in the present analysis.